NCT06137521 Risk Factors and Outcomes in Coronary Chronic Total Occlusion
| NCT ID | NCT06137521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Chronic Total Occlusion |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2010-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2010-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess the risk factors and evaluate the long-term outcomes of patients with coronary chronic total occlusion (CTO) treated with percutaneous coronary intervention or medical treatment.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years; Patients with angina or silent ischemia and documented ischemia; Patients with CTO ≥ 3months Exclusion Criteria: * eGFR\<15mL/(min·1.73m2); Chronic heart failure with NYHA grade ≥3; Had a history of coronary artery bypass grafting; Had received a percutaneous coronary intervention within the prior 3 months; Malignant tumor or immune system disorders; Pulmonary heart disease
Contact & Investigator
Fenghua Ding, PhD, MD
STUDY CHAIR
Ruijin Hospital
Frequently Asked Questions
Who can join the NCT06137521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Total Occlusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06137521 currently recruiting?
Yes, NCT06137521 is actively recruiting participants. Contact the research team at ruijindfh@126.com for enrollment information.
Where is the NCT06137521 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06137521 clinical trial?
NCT06137521 is sponsored by Ruijin Hospital. The principal investigator is Fenghua Ding, PhD, MD at Ruijin Hospital. The trial plans to enroll 3,000 participants.